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Abstract 
This paper identifies the prominent inventors (star-scientists) in the Canadian biotechnology 
co-inventorship network by taking into consideration either only patent quantity or both patent 
quantity and quality. The paper studies the positions of these stars in the network structure and 
our results show that inventors with a higher number of patents assume more central positions in 
the network: they have more collaborators, enjoy better access to information and also have 
greater control over knowledge flows in the network. Nevertheless, their network positions do 
not have higher levels of local cliquishness, suggesting that a clustered local neighbourhood may 
not have any positive impact on a scientist’s innovative productivity. We also find that the 
majority of the stars play a knowledge gatekeeping role – nurturing clusters with knowledge 
originating outside. Finally, we examine and discuss the network dynamics and the role of these 
stars in the information transmission efficiency.  
 
Keywords: star-scientists, innovation, patents, network structure, network dynamics, 
biotechnology  
JEL Classification: O31, D85, L65 
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1. Introduction 
There has been a growing recognition in the past years that top scientific individuals are a 
key driving force for the growth and innovation in biotechnology. The majority of scientists have 
very low productivity. Most of the scientific output is typically produced by the top 1% or 2% of 
scientists working in a specific area. The most productive scientists are generally called star 
scientists1: they only account for 0.8% of scientists, but are the authors of 17.3% of the published 
articles. Their productivity is thus almost 22 times higher than the average biotechnology scientist’s 
(Zucker and Darby, 1996b; Zucker et al., 1998a). The literature therefore often focuses on the 
scientific elite, their collaboration with the industry and the localized effects it creates.  
The evidence shows that the relationship between the star scientists and firms is symbiotic, as 
it contributes to the success of both the stars and their scientific performance, and the success of the 
companies and their commercial objectives. Zucker et al. (1998a) explain that locally linked star 
scientists provide access to and information about discoveries and advice to the firm concerning their 
bioscience research. Their results show that collaborative research (evidenced by coauthored 
publications) has a significant positive effect on firm performance as measured by the number of 
products in development, number of products in market and employment growth. Moreover, they 
claim that the number of star-firm collaborations powerfully predicts success: for an average firm, 
five articles coauthored by academic stars and the firm’s scientists imply about five times more 
products in development, 3.5 more products on the market, and 860 more employees. However, 
Zucker and Darby (1996b) reported that the importance of the stars for the company is much lower in 
the later stages of the development when the new techniques have already diffused widely. 
Moreover, the cooperation of the company scientists with the star scientists outside their organization 
                                                 
1 Star scientists in biotechnology were defined by Zucker and Darby (1996b) as the scientists with more than 40 
genetic sequence discoveries or 20 or more articles reporting genetic sequence discoveries by 1990. 
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is less desirable if the value of the research in question is high. Zucker et al. (1996) also relate the 
collaboration network structure in biotechnology to the value of the information in the underlying 
research project: the more valuable the information, the more likely the collaboration is confined to a 
single organization. As the expected value of research increases, star scientists are more likely to 
collaborate with scientists from their own organization. Diffusion of discoveries to other scientists 
decreases as the share of within-organization collaboration increases.  
The positive effect of the collaboration between the stars and the companies is also reflected 
in the higher scientific productivity of the stars. Zucker and Darby (1996b) suggest that stars with 
commercial ties publish at higher rate before, during and after those ties. Furthermore, scientific 
articles by stars collaborating with or employed by firms have significantly higher rates of citation 
than articles written by pure academic stars or other articles written by the same stars before or after 
the collaboration. The authors show that the presence of just one more affiliated star approximately 
doubles the expected citations received by an article. The authors speculate that this could be due to 
the fact that star scientists receive more resources from biotechnology enterprises and also do the 
work that is more highly cited while working for or with a biotechnology firm. In addition, it is 
shown that the citations to star scientists increase for those who are more involved in 
commercialization by patenting. In other words, their research shows that the scientists with patents 
are generally more widely cited than the scientists without patents, and affiliated scientists are more 
cited than linked scientists who in turn are more cited than untied scientists. Zucker et al. (1998a) 
confirm these results, and in addition they argue that those stars affiliated with firms are also very 
different in their patenting activity compared to unaffiliated university stars. Their results show that 
50% of affiliated stars have patented discoveries versus only 15.6% of the university stars. The 
patenting of discoveries by stars is an indication of expected commercial value of their discoveries.  
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The importance of geographic proximity and linkages between scientists and biotechnology 
firms are often explored in the literature. The creation of geographically bounded networks between 
university-based scientists and the companies is explained by Zucker et al. (1998a). Star scientists in 
biotechnology, who are initially typically employed by universities, appropriate much more benefits 
from their research than the employing university itself. If their research is potentially significantly 
successful, they create a spin-off company in order to appropriate the economic value of this research 
through entrepreneurial activity. These star scientists generally retain their university affiliations 
while involved in commercial applications within easy commuting distance of home or university, 
thus creating the localized effects of university research. The location of the star scientists was 
therefore found to be a principal determinant of the location of new biotechnology enterprises. 
Zucker and Brewer (1994), Zucker and Darby (1996a) and Zucker et al. (1998b) provided 
considerable evidence suggesting that the timing, location and the success of new biotechnology 
firms is primarily explained by the presence at a particular time and place of scientists who are 
actively contributing to the basic science. 
The phenomenon of star scientists has not been studied in as much details in Canada. Zucker and 
Darby (1996b) found no evidence of substantial star involvement (star affiliated with or linked to a 
biotechnology company) by Canadian biotechnology stars. Moreover, according to their results 
Canada was indicated as the major loser of key talent in biotechnology by migration (together with 
Switzerland and United Kingdom). The Canadian losses presumably reflect the ease of mobility to 
the particularly attractive US market.  
According to Queenton and Niosi (2003), however, Canadian biotechnology clusters are 
strongly related to high-class academic research and especially to the star scientists working in 
universities. Their study also highlights the importance of geographical proximity of star 
scientists for obtaining the venture capital, and for starting and growing the biotechnology firm. 
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It was confirmed that also in Canada many of the star scientists capitalise on their knowledge 
through firm start-ups. Niosi (2003) estimates that one third of Canadian biotechnology firms are 
university spin-offs. 
This paper adds to the research on the biotechnology star scientists in Canada. We propose a 
new method of identification of the star scientists, which involves both the quantity and quality 
of the patents. Moreover, we adopt a network approach and look for the positions of the star 
scientists in a complex net of innovative collaborations. We find that the inventors with a higher 
number of patents assume more central positions in the network: they have more collaborators, 
they enjoy better access to information and they also have greater control over the knowledge 
flows in the network. However, we do not find similar correlation for the level of the local 
cliquishness, which suggests that being embedded in highly clustered local neighbourhood may 
not have any positive impact on innovative productivity of the individual scientist. Finally, we 
find that the majority of the star and QQ-star scientists are also gatekeepers – the inventors 
responsible for nurturing the clusters with the knowledge originating outside.  
The paper is organised as follows: section 2 introduces the methodology and the data used in 
this study, section 3 presents several methods of identification of star scientists in Canadian 
biotechnology, section 4 studies the positions of these stars in the collaboration network and 
section 5 concludes.  
 
2. Methodology 
The patent database used for the empirical analysis is the United States Patents and 
Trademarks Office (USPTO) database. This is the only patent database which provides the 
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geographical location of the residence of each inventor. The use of the USPTO database instead 
of the CIPO may cause a certain bias in the data, which we consider minimal, since Canadian 
inventors usually patent both in Canada and in the US. The much larger and easily accessible 
American biotechnology market offers them a greater potential than the biotechnology market in 
Canada.  
Biotechnology encompasses several different research technologies and several fields of 
application. We have opted to base our USPTO search strategy on the OECD definition of 
biotechnology, which is based on the group of carefully selected International Patent Codes 
(IPC)2. An automated extraction program was used to collect the required information3 from 
biotechnology patents. All biotechnology patents granted before March 31, 2007 are included. 
According to the above definition, there are around 100 000 biotechnology patents registered at 
the USPTO. We created a patent database, which contains all patents for which at least one 
inventor resides in Canada and which comprises 3550 patents. We used the concept of social 
network analysis to create connections between the inventors from the extracted patent 
information, and with the help of the social network analysis program PAJEK we constructed 
innovation networks. An analysis of these networks enabled us to calculate various properties 
describing the position of each inventor in the network. These proprieties will be addressed in 
section 4. 
                                                 
2 The OECD definition of biotechnology patents covers the following IPC classes: A01H1/00, A01H4/00, 
A61K38/00, A61K39/00, A61K48/00, C02F3/34, C07G(11/00, 13/00, 15/00), C07K(4/00, 14/00, 16/00, 17/00, 
19/00), C12M, C12N, C12P, C12Q, C12S, G01N27/327, G01N33/(53*, 54*, 55*, 57*, 68, 74, 76, 78, 88, 92). 
3 Extracted information necessary for the research leading to this paper includes the patent number, the number of 
patent claims, the inventors’ names and their addresses. 
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We have created two different kinds of networks: First, the complete network, which 
includes all 4569 biotechnology inventors in our database which are listed as inventors or co-
inventors on any patent issued in the period of 1976 and 2007. Here we have assumed that once 
inventors unite and collaborate on one patent they continue to be in contact afterwards and are 
able to exchange information acquired long after the patent had been granted. It usually takes 
about ten years for a human health biotechnology product to reach the market and we suppose that 
inventors collaborate on the project for a large proportion of this period. It has been suggested (Dahl 
and Pedersen, 2005) that the relationships among co-inventors persist even after the project has 
ended, because they often remain in social contact and continue sharing their knowledge. This 
allows us to disregard the time of collaboration and to consider all links among inventors in the 
network as active simultaneously. We are aware that this is a strong assumption, but it is 
necessary to take into consideration the fact that our network is composed of a number of disjoint 
network components4 that do not span the entire 31 years of the database (99% of the network 
components are composed of a relatively small number of individuals and span quite short 
periods of time).  The inventors within each component could thus be considered to be inter-
connected during the whole span of the component. 
 Second, in order to track the evolution of the network positions of the star scientists over 
time we have created 16 subnetworks corresponding to five-year moving windows starting from 
1986 and finishing in 2006 (see Figure 1). As Canadian biotechnology patenting in the period 
preceding the year of 1986 is rather sporadic we decided to start with the first year when more 
than 20 Canadian biotechnology patents were issued. In addition we did not include the year 
                                                 
4 A component is a part of a network which includes a maximum number of vertices which are all directly or 
indirectly connected by links. 
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2007 as it is only partially covered in our database. Constructing the network for each year 
separately would alter the connectivity of the networks. Using only the patents granted in a given 
year would not capture the relationships created before and maintained through this particular 
year. We selected to work with the subnetworks created during the interval of five years since we 
assume that this is a minimum period length during which the relationship between any co-
inventors who appeared together on one USPTO patent lasts and during which information and 
scientific knowledge could be actively exchanged. Five-year moving windows thus more 
accurately reflect the structure of a collaboration network. 
 
3. Identification of the star scientists in Canadian biotechnology 
The resulting complete network of Canadian biotechnology inventors includes 4569 vertices 
(representing inventors) and 9731 edges (representing collaborative relations5). Based on the 
residences of inventors, we have identified 12 Canadian biotechnology clusters6: 20% of 
inventors reside in the Toronto cluster, 15% in the Montreal cluster and 9% in the Vancouver 
one. Only a very small portion of inventors (around 3%) residing in Canada live outside the 12 
defined clusters and around 29% of inventors in our sample reside outside the Canadian borders.  
The main focus of this research concerns the most inventive of the Canadian biotechnology 
researchers – the star scientists. Zucker and Darby (1996) created the definition of the 
                                                 
5 Each collaborative relation (also called a collaborative link) represents a connection between a pair of inventors, 
which involves one or more instances of co-invention of a biotechnology patent. 
6 A cluster is defined in this study as a geographically continuous region active in biotechnology (as measured by the 
patent production). 
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biotechnology star scientists based on the number of genetic sequence discoveries or the number 
of articles reporting genetic sequence discoveries. Queenton and Niosi (2003), who searched for 
biotechnology stars in Canada, included the number of genetic sequence discoveries, the number 
of publications and the number of patents in their definitions. In this research we consider patents 
as the main discriminatory indicator. We defined the prominent researchers in our dataset based 
on patent quantity only, or based on both the quantity and quality simultaneously. Moreover, we 
included the examination of the most prominent researchers based on their record of forward 
citations in scientific articles.  
First, we considered using only the number of patents as a discriminatory indicator. The 
numbers of patents authored or co-authored by each inventor are displayed in Figure 1. It is 
evident that most inventive output is produced by only a small percentage of the most prolific 
inventors some of which are listed in Table 17. We define every inventor with more than 15 
patents to be prolific; according to this classification, 51 prolific inventors in Canadian 
biotechnology are identified (which is around 1% of all inventors). Then among these, 22 
inventors are considered to be star scientists, defined here as all the inventors with more than 20 
patents. Four of the most prolific inventors have made a significantly greater contribution to the 
biotechnology innovation than other inventors and produced more than 50 patents. We shall call 
these individuals superstars. As an example, the most productive inventor in Canadian 
biotechnology has registered 151 patents. This is considerably more than any other researcher in 
the group (see Figure 1), we may be measuring a “lab director effect” here. 
                                                 
7 We have anonymised the list, the first letter represents the town of residence of the inventor and the digit subscript, 
its rank as a prolific inventor. 
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(Insert Figure 1 here) 
During our research we have observed that there are great differences in patent quality, 
which we measured by the average number of the patent claims8. Table 1 shows that the most 
prolific inventors do not necessarily register patents with the highest value. Therefore we have 
decided to incorporate patent quality as a second discriminatory factor when defining star 
scientists. We have created a Quantity and Quality Patent Index (QQ Index), which takes into 
consideration both patent counts and the mean patent value for each inventor: 
* avgi i
i avg
N C
QQI
C
=  
where 
• QQIi value of the QQ Index indicator for inventor i; 
• Ni number of patents at the USPTO invented by inventor i; 
•  average number of patent claims for all patents at the USPTO by inventor i; avgiC
• Cavg average number of patent claims for all inventors in the database. 
                                                 
8 Patent claims are a series of numbered expressions describing the invention in technical terms and defining the 
extent of the protection conferred by a patent (the legal scope of the patent). A high number of patent claims is an 
indication that an innovation is broader and has a greater potential profitability. It has been frequently suggested and 
empirically demonstrated (see for example Tong and Frame, 1994) that the number of claims is significantly and 
consistently indicative of higher value patents. The conclusions of most of the papers on patent value reviewed by 
van Zeebroeck and van Pottelsberghe de la Potterie (2006) are supportive of the positive association of the number 
of claims with patent value. Lanjouw and Schankerman (2004) have suggested that specifically in biotechnology the 
number of claims is the most important indicator of patent quality. Nevertheless, the research of Gambardella et al. 
(2008) does not provide great support for this measure. They find that the overall impact of this and other commonly 
used indicators for patent quality is in fact very small and call upon the research community to explore new and 
better determinants of the economic value of patents. We are aware of how problematic the issue of a patent value 
is, however, the number of patent claims is, to our knowledge, the best possible measure to be used in this research 
at this point. 
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This indicator modifies the number of patents according to the gap between the average 
number of claims of a particular inventor and an average number of claims for all the inventors 
in the database. For an inventor which produces patents of an average value, this indicator should 
be equal to his number of patents, whereas the other inventors can improve or worsen their 
standing depending on the average quality of their patents. According to the QQ Index we define 
a QQ-prolific inventor as one with a minimal QQ Index value of 20 (there are 50 of such 
inventors, which again represent around 1% of all the inventors) and a QQ-star inventor as one 
with an index greater than 30 (22 of such star inventors). Three inventors with the highest value 
of QQ Index are called QQ-superstars. Table 1 shows that for the most prolific inventors, the 
picture has not changed dramatically, but is slightly modified. Many inventors in the database 
however had to give up their prominent positions and, on the other hand, many have 
substantially improved their ranking. 
(Insert Table 1 here) 
The third indicator which we used to find the prominent inventors is related to the more 
scholarly side of a researcher’s qualities. The number of forward citations to the researchers’ 
articles represents a scientist’s ability to contribute to knowledge development. ISI Web of 
KnowledgeSM provides a tool to identify individuals that have made fundamental contributions to 
the advancement of science and technology in recent decades. It lists the most highly cited 
individuals within several broad subject categories for the period 1981-1999 (Later years are not 
currently available)9. The list includes only the researchers with a really extraordinary 
                                                 
9 As a consequence of the lack of the more current observations, older scientists with an extensive publication 
record probably have a better chance of being classified as star scientists because of the extensive observation 
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accomplishment, since it comprises less than 0.5% of all publishing researchers in the database. 
We have merged the data obtained from the list of highly cited scientists in biotechnology into 
our database of inventors. We have found that 28 of our inventors are also highly influential 
scientists and scholars as illustrated in the last column of Table 1. 
Surprisingly, the three distinct indicators of the prominent inventors showed quite different 
results. This methodology has enabled us to identify 101 prominent inventors (95 of them from 
Canadian clusters).Only two (T10 and S2) scientists/inventors are however indicated as prominent 
by all three measures, 24 inventors are considered to be prominent by two of the indicators, 18  
of which are concurrently identified by both the number of patents and the QQ Index. The two 
measures are obviously much more correlated together than with the indicator of highly cited 
scientists. For example, two of the five existing superstars are also QQ-superstars and two others 
are QQ-stars. The remaining 75 inventors were identified as prominent by only one measure. 
Among them, one QQ-superstar scientist falls to the 57th rank if the patent value is not taken into 
consideration and many other QQ-prolific inventors would occupy a rank as low as the 361st 
rank. The value of a patent hence seems to be an important discriminatory factor. Furthermore, 
some of the highly cited inventors reach even lower positions based on the other two indicators 
(as low as 1956th rank), since eight of the highly cited scientists have only one biotech patent at 
the USPTO, while six of them appear as inventors only on two patents. Moreover, the fact that 
we found only 28 matching scientists in both lists suggests that there must also be many highly 
influential biotechnology researchers (as acknowledged by their citing colleagues) who never 
                                                                                                                                                             
period, whereas younger scientists who already belong to the very top of their class may still not be included 
because they have not yet accumulated enough publications and citations.  
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filed any patent application at the USPTO10. We assume that these highly cited scientists come 
mostly from an academic environment, where the publication performance is more appreciated 
and more rewarding than impressive patent scores. The scientists with the most prolific 
publication record may thus often neglect patent application opportunities. A much less probable 
explanation is that these highly cited scientists simply patent their inventions at different patent 
offices (e.g. CIPO or EPO). 
Table 2 presents the results per cluster by including all the discussed measures. Toronto is 
the leader in the number of prominent scientists in the cluster (44 scientists out of which 4 are 
superstars) while Montreal and Vancouver are far behind (16 and 9 scientists, respectively). In 
terms of sheer number of patents, Toronto excels (15 stars) but when the quality is taken into 
consideration, Montreal has in fact more QQ-star scientists who produce patents of high value 
than Toronto (11 stars compared to 7 stars). The Toronto cluster also houses the highest number 
of scientists with an outstanding citation record (12 scientists), whereas Montreal is lagging 
behind with only 3 highly cited scientists in the database. Vancouver’s record is more modest on 
all fronts (it has virtually no star and only 3 prolific scientists), except the indicator of highly 
cited researchers (with 6 such scientists). The small clusters of Kingston, Halifax and Sherbrooke 
do not enjoy the benefits of any prominent scientist. 
(Insert Table 2 here) 
                                                 
10 The difference in the publication and patent records has been already observed at the Japanese corporate scientists 
in the pharmaceutical industry (Furukawa and Goto, 2006). The most frequently publishing scientists did not apply 
for a considerably greater number of patents than other researchers in their companies, but they had a positive effect 
on the number of patent applications filed by their co-authors. 
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To conclude this section, we found it very fruitful to use the multi-indicator approach for the 
analysis of the prominent scientists. The picture became much more complete when we included 
the patent value in the equation instead of the sole patent count. We found that star scientists or 
highly prolific biotechnology inventors do not necessarily author or co-author patents of the 
highest value. By taking into consideration patent quality, the ranking of star and prolific 
inventors has changed. Not all prominent and highly cited researchers and scientists in 
biotechnology produce patents or register them at the USPTO, and for those that do, their patents 
are not of the highest value in terms of number of claims.  
 
4. The position of the star and QQ-star scientists in the network 
This section investigates the positions of the stars and QQ-stars in the Canadian 
biotechnology collaboration network. Moreover, we explore the level of overlapping of the 
prominent researchers and the gatekeepers, which are Canadian inventors who due to their 
strategic positions in the network enable the nurturing of clusters with fresh knowledge 
originating outside (Schiffauerova and Beaudry, 2009a). 
 
4.1 Hypotheses 
We expect to find evidence of the crucial role played by star scientists in biotechnology 
networks by occupying very central network positions. The central position in the network 
structure usually implies that star scientists are connected to a much larger number of inventors 
than others. Obviously, the identification of both the star or QQ-star scientists is directly related 
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to the number of patents they produced and thus we can certainly assume that the scientists with 
higher number of patents or higher QQ Index score will have a higher number of collaborators. 
Our first hypothesis can read as follows: 
• Hypothesis H1a: The inventors with a higher patent production have more collaborators. 
• Hypothesis H1b: The inventors with a higher QQ Index have more collaborators. 
 
Since the inventors with a higher number of patents are usually more central they are also 
much better interconnected in the complex net of interrelationships. The central network position 
of the star or QQ-star scientists enables them to reach all other inventors in the network faster, 
because the length of the shortest paths11 between them and other inventors is usually greatly 
reduced due to the numerous connections they have. As a consequence, the stars and QQ-stars 
are able to get a much improved access to knowledge in the network. This brings us to the 
second hypothesis: 
• Hypothesis H2a: The inventors with a higher patent production enjoy better access to 
information because of the reduced shortest paths to all the other inventors in the 
network. 
• Hypothesis H2b: The inventors with a higher QQ Index enjoy better access to information 
because of the reduced shortest paths to all the other inventors in the network. 
 
We expect that the star and QQ-star inventors will also have more strategic positions in the 
network in terms of their ability to control the flow of information between other inventors. Their 
                                                 
11 The length of the shortest path depends on the number of intermediaries needed for an inventor to reach another 
inventor in the network. 
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highly central positions enable them to act as intermediaries for the transfer of knowledge 
between many other inventors in the network. This increased flow of knowledge thus gives them 
a greater power over the knowledge distribution among others. The existence of the star and QQ-
star inventors is thus crucial for a great number of other inventors in the network and their 
disappearance from the network would not only slow down the knowledge flow in the whole 
network by increasing the lengths of the shortest paths among many others, but it would also 
completely disconnect many inventors and thus highly limit their knowledge sources. Therefore 
we suppose that the inventors with a higher number of patents or QQ Index scores should have 
more strategic network positions and thus have control over a greater flow of information, hence 
the third hypothesis: 
• Hypothesis H3a: The inventors with a higher patent production have control over a 
greater amount of knowledge which passes through them. 
• Hypothesis H3b: The inventors with a higher QQ Index have control over a greater 
amount of knowledge which passes through them. 
 
We also suppose that the local neighbourhood of the star and QQ-star inventors will be more 
cliquish12. The stars or QQ-stars have direct or indirect access to a larger number of other 
innovators and we therefore assume that their local environment will be also more dense and 
cohesive. This should support friendship and trust-building, and thus facilitate collaboration 
between the innovators. We thus expect that this will also be a contributing factor to the success 
of the stars and QQ-stars, which leads to our fourth hypothesis: 
                                                 
12 Cliquishness refers to the likelihood that two inventors who are both connected to the same third inventor are also 
connected to each other. 
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• Hypothesis H4a: The inventors with a higher patent production are positioned in more 
cliquish local neighbourhoods. 
• Hypothesis H4b: The inventors with a higher QQ Index are positioned in more cliquish 
local neighbourhoods. 
 
We expect that star and QQ-star inventors will also play a crucial role in the nurturing of 
clusters with fresh knowledge originating outside. They have more collaborators and we suppose 
that many of these reside in different clusters or even countries. The abundant connections 
outside their own clusters should enable the stars and QQ-stars to serve as knowledge 
gatekeepers - as procurers of external knowledge for other inventors which collaborate less or 
focus on joint research within the same region. The star and QQ-star inventors will thus be 
among the few inventors who are responsible for the inflow of external information to the cluster 
and will also play much more important role in nurturing of clusters with fresh outside 
knowledge, which brings us to our fifth hypothesis. 
• Hypothesis H5a: The inventors with a higher patent production play more important role 
as gatekeepers for the clusters in which they reside. 
• Hypothesis H5b: The inventors with a higher QQ Index play more important role as 
gatekeepers for the clusters in which they reside. 
 
Similarly, we assume that the importance of the star and QQ-star inventors as procurers of 
external knowledge for Canada will also be much higher than the importance of less prolific 
inventors. Now we are interested in the more general impact of inventors which import the 
external knowledge to other Canadian inventors and the importance of that knowledge for 
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Canada in terms of its contribution to the innovative potential. Our sixth hypothesis therefore 
proposes that the inventors with higher number of patents or higher QQ Index will also play 
much more important role as procurers of outside knowledge for Canada: 
• Hypothesis H6a: The inventors with a higher patent production play more important role 
as gatekeepers for Canada. 
• Hypothesis H6b: The inventors with a higher QQ Index play more important role as 
gatekeepers for Canada. 
 
4.2 Methodology and results 
In order to validate the above hypotheses we use the most common measure of correlation – 
the Pearson Product Moment Correlation, which reflects the degree of linear relationship 
between two variables. We calculate the correlation coefficients for each two variables for every 
hypothesis as explained in Table 3. Various indicators of the structural network properties13 are 
used as variables representing the attributes of the inventors’ positions: The number of 
collaborators of each inventor in H1 is calculated as the degree centrality, which measures the 
number of lines that are connected to each vertex. The closeness of the inventors to all other 
inventors in the network in H2 is measured by the closeness centrality of each vertex expressed 
as the number of other vertices divided by the sum of all distances between the vertex and all 
others. However, since closeness centrality is calculated only among the inventors who are 
directly or indirectly interconnected, it would be misleading to use this measure for all of them. 
The vertices in small components would show very high centralities, because all the inventors 
                                                 
13 For a more detailed description of the network properties (degree centrality, closeness centrality, betweenness 
centrality and average egocentric density), see Wasserman and Faust (1994) or de Nooy et al. (2005). 
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are close to each other, but it would not reveal much about their centrality in comparison with the 
inventors included in other components. We expect that the total correlation would then be 
greatly underestimated. Therefore, we include in the testing for H2 only the inventors who are 
interconnected in the largest network component. The amount of information which passes 
through each inventor in H3 is calculated with the betweenness centrality of each vertex, which 
measures the proportion of all shortest distances between pairs of other vertices that include this 
vertex. Average egocentric density, which is a fraction of all pairs of the immediate neighbours 
of a vertex that are also directly connected to each other, is used to measure the degree of local 
cliquishness for each inventor in H4. Finally, in hypotheses H5 and H6 we use the indices defined 
in Schiffauerova and Beaudry (2009a): Gatekeeper’s Importance Index for Cluster (GIcluster 
Index) and Gatekeeper’s Importance Index for Canada (GICanada Index)14, each calculated for 
every vertex in the network. 
(Insert Table 3 here) 
The resulting values of the correlation coefficients calculated in the complete network are 
shown in Table 4. Since for large samples it is usually easy to achieve significance of the 
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஼ܲ d
clu
•  ܤ௜…betweenness centrality of the inventor ݅ 
correlation, all of our correlation coefficients were found highly significant. The strength of the 
relationship was thus used to determine if the relationship explains very much or not. 
(Insert Table 4 here) 
The resulting values of the correlation coefficients calculated in the 16 subnetworks are 
shown in Table 5. Since the sizes of the subnetworks are smaller than the size of the complete 
network, the significance (at the 0.01 or 0.05 levels) was not achieved for some of the results. 
For most of the results however the strength of the relationship could have been used for the 
hypotheses validation. The variables were considered uncorrelated if r < 0.1, weakly correlated if 
0.1 < r < 0.3, moderately correlated if 0.3 < r < 0.5 and strongly correlated if 0.5 < r < 1.00.  
(Insert Table 5 here) 
The results for each hypothesis are summarized in Table 6 and Table 7. The correlations 
were found to be very strong in both hypotheses H1a and H1b when calculated in the complete 
network and moderately strong when calculated in the subnetworks. The correlations between 
these values were expected, since the number of collaborators of an inventor is usually related to 
the number of his patents. By every jointly created invention leading to a new patent the inventor 
usually also gains new collaborators (unless he continues to work always with the same group of 
inventors in all of his patents). Also the more central positions of the inventors with a higher 
number of patents (or higher QQ Index scores) were confirmed in both H2a and H2b and both 
H3a and H3b, even though for H2b and H3b the relationship was found to be weak in most of the 
subnetworks We confirmed that the most important inventors in terms of patent counts and 
patent quality do play more important roles in the networks. They have a better ability to reach 
all the knowledge in the network due to the reduced length of the shortest paths to all other 
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inventors. Moreover, their positions are highly strategic, since they enable them to assume 
control over a great flow of information.  
Hypotheses H4a and H4b were however confirmed neither in the complete network nor in 
the subnetworks. The inverse but extremely weak relationships between the number of patents or 
level of QQ Index and the level of the local cliquishness of an inventor were found to exist. This 
means that our assumption of dense and cohesive relationships supporting friendship and trust-
building, thereby facilitating collaboration between the innovators and thus contributing to the 
innovativeness was not supported. The research carried out in the area of network cliquishness 
has also not been conclusive so far. On the one hand, Uzzi and Spiro (2004) and Schiling and 
Phelps (2007) show that high cliquishness in the networks enhances the system`s innovative 
performance. On the other hand, the empirical findings of Fleming et al. (2006) prove the 
negative impact of the higher degree of cliquishness in the network on the innovative 
productivity. The authors argue that there is an optimal degree of cliquishness that depends on a 
variety of factors. Cowan and Jonard (2003) identify both positive and negative effects of high 
cliquishness on knowledge growth. They argue that the net effect is determined by both the benefits 
from differentiated neighbourhoods (agents in various neighbourhoods highly differ) and the loss due 
to repetition (cliquishness duplicates transmissions). The very weak negative correlation we 
obtained makes us lean towards the view that there are negative effects of high cliquishness on 
knowledge growth. More empirical research is needed to clarify this relationship. 
Finally, the two hypotheses related to the gatekeepers have mixed results. The importance of 
a gatekeeper as the procurer of external knowledge for the cluster in which he resides in H5a and 
H5b proved to be only very weakly correlated to the number of patents or QQ Index; however the 
importance of gatekeeper for Canada was found to be either strongly (H6a) or moderately (H6b) 
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correlated. This is not surprising, since the number of patents or QQ Index are calculated 
globally as is the GICanada Index but GIcluster Index reflects only the local role of the intermediary 
in his own cluster. His role could be very significant in certain smaller or medium-sized clusters, 
but at the same time quite negligible in terms of his contribution to the overall Canadian 
innovative potential. Due to the limitations of our data, the strength of these four relationships 
(H5a, H5b, H6a and H6b) was calculated only in the complete networks, but not in the 
subnetworks. 
(Insert Table 6 here) 
4.3 Are stars and QQ-stars also gatekeepers? 
The next step involves the identification of the level of overlap between the star or QQ-star 
inventors and the gatekeepers as defined by Schiffauerova and Beaudry (2009a). Since the 
correlation between the patent counts or QQ Index and the Gatekeeper’s Index of Importance for 
Canada is confirmed, we want to see how many of the stars or QQ-stars are also gatekeepers of 
significant importance for Canada. Table  shows absolute and relative numbers of the star, QQ-
star and highly cited scientists who belong to the five categories15 of inventors based on their 
network positions and the level of the Gatekeeper’s Index of importance for Canada, as they 
were defined in Schiffauerova and Beaudry (2009a). Internal and external inventors do not 
participate in the transmission of external knowledge to the cluster, since they lack either the 
connection outside their cluster (internal inventors) or inside their cluster (external inventors). 
These inventors constitute the majority of inventors in all the clusters. The stars, QQ-star of 
                                                 
15 internal inventors (only intra-cluster collaborations), external inventors (only inter-cluster collaborations), 
redundant intermediaries (intermediaries with betweenness = 0), gatekeepers (intermediaries with 0 ‹ GIcluster ‹ 0.001) 
and important gatekeepers (intermediaries with GIcluster › 0.001) 
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highly cited scientists are rarely external inventors, but around 14% of stars, 45% of QQ-stars 
and 22% of highly cited scientists are internal inventors who collaborate exclusively within their 
own cluster. Inventors which do maintain both intra-cluster and inter-cluster collaborations, but 
do not serve as indispensible intermediaries for other inventors are called redundant 
intermediaries. Such intermediaries bring redundant external knowledge to the cluster, since not 
only would their disappearance not reduce the amount of transmitted external knowledge but it 
would not even make the shortest path for that transmission longer. These inventors could be 
theoretically still quite productive and thus considered important creators of biotechnology 
innovation, but they are not essential as external knowledge procurers. As the results in Table 8 
show, there are no stars or QQ-stars among the redundant intermediaries, but 22% of highly 
cited scientists belong to this inventor category. Gatekeepers are the intermediaries which do 
introduce non-redundant knowledge to the cluster and thereby contribute to the innovative 
potential of other inventors in Canada. The inventors with the top highest scores of GICanada 
Index are called here very important gatekeepers. The table shows that 86% of all star inventors 
are gatekeepers (27% are gatekeepers and 59% are very important gatekeepers), 55% of all QQ-
stars are gatekeepers (23% are gatekeepers and 33% are very important gatekeepers) and 49% of 
all the highly cited scientists are gatekeepers as well (27% are gatekeepers and 22% are very 
important gatekeepers).  
(Insert Table 8 here) 
Thus we can conclude that the majority of the star and QQ-star scientists are also 
gatekeepers. However, the relationship between the stars and the gatekeepers seems to be 
stronger than the relationship between the QQ-stars and the gatekeepers. This was expected 
since there the GI indices do not involve the patent quality. This was also confirmed by the 
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correlation coefficients in the previous analysis, which were showing somewhat higher strength 
for the relationship between the number of patents and GICanada Index (Hypothesis H6a) and also 
in all the cases of the vertex centralities (Hypotheses H1a, H2a and H3a) than for the same 
relationships with the QQ Index (Hypotheses H1b, H2b, H3b and H6b). This suggests that even if 
the QQ Index may be a more accurate measure of the inventor’s importance in terms of his 
inventive contribution as it reflects both the quantity and the quality of his patents, it is less 
accurate when assessing the importance of the position for the inventor in the network and his 
importance as gatekeeper. It is the number of patents but not the quality of these patents, which 
is related to the ability of the inventor to acquire external knowledge and to nurture the clusters 
with information from outside. The inventor with a high number of patents usually benefits from 
a denser and more developed network of social connections. This enhances speed and likelihood 
of his access to the outside knowledge. Moreover, multiple sources of information enable him to 
acquire alternative interpretations of problems and their potential solutions. The richer and 
greater amounts of information and knowledge are thus exchanged and integrated among his 
fellow colleagues from the same cluster. The typically abundant connections within the cluster 
further facilitate the dissemination of the acquired knowledge. Star scientists are thus very well 
equipped to play the gatekeeping role in the network. 
 
4.4 Star and QQ-star scientists: the dynamic perspective 
The final section takes a dynamic perspective and explores the evolution of the 
biotechnology field in Canada with the focus on the innovation network structure and the 
network’s most central inventors – star and QQ-star scientists. 
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Figure 2 shows an average number of patents produced or co-produced per inventor in each 
of the 16 intervals. On average, inventors became more productive over the years. Their 
patenting activity peaked in the years of 2000-2003. In fact, in 2002, biotechnology was 
considered to be one the most dynamic and fastest growing fields in Canada. According to the 
Statistics Canada (2005), biotechnology companies have more than quadrupled their revenues in 
1997-2003. By 2002, Canada was the second most active country in the world in biotechnology 
in terms of new firms, venture capital and patents, after the US and ahead of the UK (Niosi, 
2005). Metrics such as R&D spending, market capitalization as well as total number of firms and 
revenues all showed strong growth over the five years preceding 2002 (Ernst and Young 2002). 
It is however evident from Figure 2 that after the peak in 2001-2002 the number of 
biotechnology patents invented or co-invented by Canadians has been decreasing. In the recent 
survey of Statistics Canada (2007) it was found that the number of innovative biotechnology 
firms increased only by 9% in the period of 2003-2005, whereas it increased by 31% between 
2001 and 2003. Niosi (2006) noted that in recent years (particularly since 2000), Canadian 
biotechnology companies have experienced financing problems and even some of the well-
financed firms have abandoned the field altogether. He suggests that the new trend of Canadian 
biotechnology is directed towards concentration of activity into a small number of dedicated 
biotechnology companies. 
(Insert Figure 2 here)          (Insert Figure 3 here) 
Figure 3 confirms the diminishing activity in biotechnology innovation by slightly 
decreasing tendency of the average number of granted patents per inventor after the peak in 
2002.  In the light of this evolution it is interesting to note that even though the average number 
of patents per inventor has decreased in the latest years, the average degree of a vertex in the 
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subnetworks still maintains its increasing trend. This suggests that an average inventor has a 
tendency to collaborate on a lower number of patents with increasingly more inventors. This 
could mean that the projects an average inventor works on have become increasingly more 
complex and require expertise from more specializations. The projects consequently involve 
more collaborators and the patents end up being registered in the name of more co-inventors than 
previously. Another explanation is that the collaborations between the partners became less 
repetitive, i.e. an average inventor collaborates with different collaborators than previously or 
changes his collaborators more often than before. A possible reason for that might be his more 
rapidly changing needs for different kinds of knowledge. Further insights are necessary in order 
to understand the dynamics of the collaboration in Canadian biotechnology.  
The next step is to explore the evolution of the occurrence of the phenomenon of the star 
scientist in Canadian biotechnology. Figure 4 and Figure 5 show the development of the numbers 
of star and QQ-star scientists in Canadian biotechnology sector. Figure 4 shows that the total 
number of stars and QQ-stars was steadily raising during the first 15 years of our observation 
period, whereas in the last 5 years the absolute numbers of active stars and QQ-stars have not 
changed much. Consequently, the share of stars and QQ-stars in the total number of inventors 
has been decreasing or stagnating during the last decade (see Figure 5). Both trends are 
observable for highly cited scientists as well, even though in smaller scale. This development 
might be related to the general decreasing trend in biotechnology innovation in Canada observed 
in Figure 2, but it may also suggest that the network has reached a certain critical mass of highly 
central inventors (stars or QQ-stars), which is sufficient for the smooth knowledge transmission 
and efficient communication in the network. 
(Insert Figure 4 here)          (Insert Figure 5 here) 
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In order to better understand the role of the most prominent biotechnology inventors within 
the innovation network we measured network centralization and followed the dynamics of this 
indicator as well. A highly centralized network has a clear boundary between the center (central 
inventors) and the periphery (other inventors). Inventors in more central network positions 
(inventors with higher values of centrality) have more potential sources of scientific knowledge 
at their disposal and better opportunities to spread information further. This makes them 
important for the transmission of information through the network. Centralization of a network is 
defined as the variation in the centrality of vertices, divided by the maximum degree variation 
which is possible in a network of the same size (de Nooy et al., 2004). There are two main 
indicators of network centralization which could be measured in disconnected networks: degree 
centralization and betweenness centralization. Degree centralization of a network is based on the 
variation in degree centrality of vertices in the network, whereas betweenness centralization of a 
network is based on the variation in their betweenness centrality.  
(Insert Figure 6 here)          (Insert Figure 7 here) 
Figure 6 and Figure 7 show the evolution of both indicators of centralization. Even though 
both measures fluctuate significantly, they have fairly observable tendencies. The indicator of 
degree centralization shows that the network might have become slightly more centralized over 
time, meaning that the star and QQ-star scientists only mildly improve their access to knowledge 
in the network through slightly increasingly higher numbers of collaborators. However, it is a 
decreasing tendency which is observable in the indicator of betweenness centralization. This 
means that star and QQ-star scientists do not seem to gain more strategic positions and to assume 
increasingly more control over a greater flow of information in the network. In general it could 
be stated that more central inventors have not become more central over time.  
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This development is somewhat reminiscent of the one we observed in nanotechnology. 
However, the nanotechnology sector experiences gradual network decentralization due to an 
increasing specialization of the field. A few highly central nanotechnology inventors are slowly 
disappearing and more inventors in less central positions within numerous nanotechnology 
specializations emerge (Schiffauerova and Beaudry, 2009b). This is not the case of 
biotechnology and the results we obtained for biotechnology sector are thus rather surprising. We 
have expected that in the generally rapidly expanding network (at least first 15 years) such as the 
one of biotechnology innovation, the central inventors will be gaining unproportionally more 
connections than others over time and thus will become more central over time. The fact that the 
inventors in the transmission centre of the biotechnology subnetworks (stars and QQ-stars) are 
becoming slightly less central with time raises a question of the importance of the centralized 
network structure and the role of the star and QQ-star scientists in the information transmission 
efficiency. Could decreasing centralization in fact mean that the star and QQ-star scientists are 
gradually getting less important for the effective knowledge flows?  Further research is needed to 
answer this question. 
 
5. Conclusions 
This paper studies innovation in Canadian biotechnology clusters. Drawing from the lists of 
inventions from the USPTO website, we have created a complete database of all registered 
patents in biotechnology, for which at least one inventor or co-inventor resides in Canada. We 
determined the greatest concentrations of biotech activity and identified 12 Canadian 
biotechnology clusters. The first objective of this work was the identification of the prominent 
researchers in Canadian biotechnology clusters. We proposed to take into consideration the 
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patent quality when identifying the prolific inventors, and developed a measure which includes 
both the patent count and the patent value in the equation. We observed that star scientists or 
highly prolific biotechnology inventors do not necessarily author or co-author patents of the 
highest value. Furthermore, we have also identified the scientists whose publications are the 
most highly cited. We discovered that not all the prominent researchers and superior scientists in 
biotechnology produce patents or register them at the USPTO. We offered an explanation based 
on the differences in the reward systems in academic and industrial environments. 
In the second part we have studied the positions of the stars and QQ-stars in the network 
structure. Our results show that the inventors with higher number of patents and the higher QQ 
Index assume more central positions in the network: they have more collaborators, they enjoy 
better access to information because of the reduced shortest paths to all the other inventors in the 
network and they also have greater control over the knowledge flows in the network since much 
more information passes through them. Nevertheless, we did not confirm our hypothesis 
regarding the level of cliquishness in the inventor’s neighbourhood: The inventors with a higher 
number of patents or levels of QQ Index do not assume the network positions with a higher level 
of the local cliquishness. The impact of cliquishness of individual inventors on their innovative 
propensity has not been empirically studied so far and the existing research regarding the 
innovative performance of the networks with various degrees of cliquishness has not been 
conclusive. The very weak negative correlation however makes us lean towards the view that 
there may in fact be also negative effects of high cliquishness on knowledge growth as was 
proposed by Cowan and Jonard (2003) and empirically supported by Fleming et al. (2006). 
Finally, we investigated the relationship between the stars or QQ-stars and the gatekeepers. 
We found that the great majority of star inventors (86%) and of QQ-star inventors (55%), and 
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almost half of all the highly cited scientists (49%) are also gatekeepers responsible for the inflow 
of external knowledge which highly contributes to the Canadian innovative potential. However, 
we observed that it is only the number of patents but not the quality of these patents, which is 
related to the ability of the inventor to acquire external knowledge and to nurture the clusters 
with information from outside. Star scientists with their usually abundant connections outside 
and inside clusters are thus best equipped to play the gatekeeping role in the network.  
The last section of the article involved an exploration of the evolution of the innovation 
network structure of Canadian biotechnology sector. We have shown that after the phenomenal 
growth evidenced by the steeply increasing annual numbers of patents during the Canadian 
biotechnology peak years (2000-2004), the number of biotechnology patents invented or co-
invented by Canadians has been decreasing. Also, both absolute and relative numbers of stars 
and QQ-stars have been stagnating for last 8-10 years. It was suggested that this development 
might be related to the general decreasing trend in biotechnology innovation in Canada, or that 
the network has reached a certain critical mass of highly central inventors (stars or QQ-stars), 
which is sufficient for the smooth knowledge transmission and efficient communication. 
Moreover, we observed that the inventors in the transmission centre of the networks (stars and 
QQ-stars) are becoming slightly less central with time. This raised the question of the 
importance of the centralized network structure for the effective knowledge flows and the role of 
the star scientists in the information transmission efficiency.  
This paper is yet another step towards the understanding of the influence of knowledge 
networks on the innovative activities of firms located within high technology clusters. We intend 
to continue exploring the exact role played by networks and their importance in the chain of 
knowledge creation. One avenue for future research is to gather information about the affiliation 
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for each star scientist and gatekeeper in order to better understand from which environment they 
arise: academics, industrial or governmental inventors. Moreover, we plan to include the 
networks arising from cooperation on the scientific articles in the overall network of innovators. 
This will allow us to study the influence of the nature and the structure of the networks of 
various innovators (i.e. inventors and scientists) on the propensity to innovate of firms in 
clusters. We also intend to merge the database of the inventors (patents) and the database of the 
scientists (articles) to gain a full picture of the innovation production in Canadian biotechnology. 
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Figure 1: Distribution of the number of patents authored or co-authored by each inventor 
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Figure 2: Number of patents and number of inventors 
in each interval  
 
Figure 3: Average degree of a vertex and average 
number of patents produced or co-produced per 
inventor in each interval 
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Figure 4: Number of inventors which are stars (or 
prolific), QQ stars (or QQ prolific) and highly cited 
scientists in each period 
Figure 5: Share of inventors which are stars (or 
prolific), QQ stars (or QQ prolific) and highly 
cited scientists in each period 
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Figure 6: Evolution of degree centralization of 
Canadian biotechnology network  
 
Figure 7: Evolution of betweenness centralization of 
Canadian biotechnology network 
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Table 1: Positions of all prominent inventors according to three different measures 
Inventor* 
Number of patents Average
# of 
claims 
  Quantity and Quality Patent Index Highly cited 
scientist Ranking Patent count Ranking QQI value 
T1 1 151 superstar 12 1 110,25 QQ-superstar 
T2 2 61 superstar 12 3 44,54 QQ-superstar 
T3 3 56 superstar 11 11 37,48 QQ-star 
T4 4 52 superstar 10 21 31,64 QQ-star 
T5 5 44 star 11 24 29,45 QQ-prolific 
M1 6 42 star 14 12 35,78 QQ-star 
O1 7 41 star 14 13 34,92 QQ-star 
S1 8 39 star 16 10 37,97 QQ-star 
T6 9 36 star 15 19 32,86 QQ-star 
T7 10 33 star 12 33 24,09 QQ-prolific 
T8 10 33 star 9 65 18,07 
T9 12 32 star 13 32 25,31 QQ-prolific 
T10 13 28 star 16 28 27,26 QQ-prolific highly cited
C1 14 26 star 10 74 15,82 
T11 14 26 star 25 7 39,55 QQ-star 
T12 14 26 star 12 55 18,98 
T13 17 25 star 15 40 22,82 QQ-prolific 
T14 17 25 star 15 40 22,82 QQ-prolific 
O2 19 24 star 15 43 21,90 QQ-prolific 
S2 20 23 star 24 17 33,59 QQ-star highly cited
E1 21 21 star 9 136 11,50 
T15 21 21 star 9 136 11,50 
C2 23 20 prolific 16 53 19,47 
T16 23 20 prolific 11 98 13,39 
O3 25 19 prolific 16 60 18,50 
O4 25 19 prolific 12 93 13,87 
Q1 25 19 prolific 16 60 18,50 highly cited
T17 25 19 prolific 11 108 12,72 
C3 29 18 prolific 25 27 27,38 QQ-prolific 
C4 29 18 prolific 21 37 23,00 QQ-prolific 
E2 29 18 prolific 18 52 19,71 highly cited
O5 29 18 prolific 12 102 13,14 
T18 29 18 prolific 31 16 33,95 QQ-star 
T19 29 18 prolific 17 58 18,62 
T20 29 18 prolific 17 58 18,62 
T21 29 18 prolific 9 173 9,86 
T22 29 18 prolific 9 173 9,86 
T23 29 18 prolific 9 173 9,86 
T24 39 17 prolific 16 72 16,55 
T25 39 17 prolific 9 200 9,31 highly cited
T26 39 17 prolific 8 228 8,27 
V1 39 17 prolific 7 294 7,24 highly cited
C5 43 16 prolific 18 66 17,52 
C6 43 16 prolific 12 129 11,68 
E3 43 16 prolific 8 253 7,79 
E4 43 16 prolific 6 390 5,84 
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Inventor* 
AverageNumber of patents   Quantity and Quality Patent Index Highly cited 
# of 
claims 
scientist Ranking Patent count Ranking QQI value 
M2 43 16 prolific 10 177 9,73 
O6 43 16 prolific 14 95 13,63 
O7 43 16 prolific 12 129 11,68 
T27 43 16 prolific 19 60 18,50 
T28 43 16 prolific 18 66 17,52 
T29 52 15 22 46 20,08 QQ-prolific 
M3 57 14 61 2 51,96 QQ-superstar 
V2 57 14 28 35 23,85 QQ-prolific 
M4 67 13 49 9 38,76 QQ-star 
O8 67 13 44 14 34,80 QQ-star 
T30 67 13 33 29 26,10 QQ-prolific 
T31 67 13 33 29 26,10 QQ-prolific 
F1 79 12 39 25 28,47 QQ-prolific 
T32 79 12 38 26 27,74 QQ-prolific 
T33 79 12 14 163 10,22 highly cited
M5 94 11 36 33 24,09 QQ-prolific highly cited
F2 130 9 42 37 23,00 QQ-prolific 
M6 130 9 75 4 41,07 QQ-star 
M7 130 9 75 4 41,07 QQ-star 
M8 130 9 74 6 40,52 QQ-star 
M9 130 9 61 18 33,40 QQ-star 
O9 130 9 42 37 23,00 QQ-prolific 
F3 158 8 41 47 19,96 QQ-prolific 
F4 158 8 41 47 19,96 QQ-prolific 
F5 158 8 41 47 19,96 QQ-prolific 
M10 158 8 80 8 38,94 QQ-star 
M11 158 8 71 15 34,56 QQ-star 
M12 158 8 64 22 31,15 QQ-star 
O10 158 8 41 47 19,96 QQ-prolific 
T34 158 8 46 42 22,39 QQ-prolific 
T35 158 8 11 451 5,35 highly cited
M13 204 7 77 20 32,79 QQ-star 
M14 204 7 71 23 30,24 QQ-prolific 
O11 266 6 60 43 21,90 QQ-prolific 
V3 266 6 64 36 23,36 QQ-prolific 
W1 266 6 9 821 3,29 highly cited
S3 361 5 68 45 20,69 QQ-prolific highly cited
T36 361 5 7 1368 2,13 highly cited
V4 361 5 84 31 25,55 QQ-prolific 
T37 718 3 12 1270 2,19 highly cited
T38 718 3 6 2479 1,10 highly cited
out1 1067 2 6 3080 0,73 highly cited
T39 1067 2 9 2479 1,10 highly cited
V5 1067 2 15 1536 1,83 highly cited
V6 1067 2 11 2067 1,34 highly cited
V7 1067 2 8 2699 0,97 highly cited
V8 1067 2 6 3080 0,73 highly cited
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Inventor* 
AverageNumber of patents   Quantity and Quality Patent Index Highly cited 
# of 
claims 
scientist Ranking Patent count Ranking QQI value 
M15 1956 1 8 3678 0,49 highly cited
M16 1956 1 4 4184 0,24 highly cited
T40 1956 1 26 1774 1,58 highly cited
T41 1956 1 17 2607 1,03 highly cited
T42 1956 1 15 2831 0,91 highly cited
T43 1956 1 10 3402 0,61 highly cited
T44 1956 1 5 4074 0,30 highly cited
V9 1956 1 38 1238 2,31 highly cited
 
* T# … Toronto inventor C# … Calgary inventor Q# … Quebec inventor 
   M# … Montreal inventor S# … Saskatoon inventor out# … inventor outside cluster 
   V# … Vancouver inventor W# … Winnipeg inventor F#… foreign inventor  
   E# … Edmonton inventor O# … Ottawa inventor   
 
Table 2: Prominent inventors by cluster 
Biotechnology 
cluster 
Stars (superstars)a Prolific inventors b Highly 
cited 
scientists 
All prominent researchers 
Number 
of patents 
QQ 
Index 
Number 
of patents 
QQ 
Index 
Total 
number 
as % of all 
inventors 
Toronto 15 (4)* 7 (2)* 28 18 13 44 (4 )* 4.75% 
Montreal 1 11 (1)* 2 13 3 16 (1)* 2.29% 
Vancouver   1 3 6 9 2.19% 
Edmonton 1  4  1 4 1.90% 
Calgary 1  6 2  6 6.59% 
Saskatoon 2 2  3 2 3 2.04% 
Winnipeg     1 1 1.30% 
Ottawa 2 2 7 5  11 4.91% 
Quebec   1  1 1 0.79% 
a  The numbers in brackets denote the number of these stars that are considered to be superstars in the cluster. 
b All prolific inventors (including stars and superstars) 
 
Table 3: The examined variables for each hypothesis 
H# Variable #1 Variable #2  H# Variable #1 Variable #2 
H1a  
 
# of patents 
degree centrality H1b  
 
QQ Index 
degree centrality 
H2a closeness centrality H2b closeness centrality 
H3a betweenness centrality H3b betweenness centrality 
H4a avg egocentric density H4b avg egocentric density 
H5a GI
cluster Index H5b GI
cluster Index 
H6a GI
Canada Index H6b GI
Canada Index 
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Table 4: Pearson correlation coefficients calculated in the complete network 
 Degree 
centrality 
Closeness 
centrality 
Betweenness 
centrality 
Avg egocentric 
density 
GIcluster 
Index 
GICanada 
Index 
# of patents 0.594** 0.391** 0.454** -0.118** 0.237** 0.510** 
QQ Index 0.550** 0.344** 0.344** -0.085** 0.184** 0.370** 
** Correlation is significant at the 0.01 level 
 
Table 5: Pearson correlation coefficients calculated in the subnetworks 
#of patents QQ Index 
Interval 
 
Degree 
centrality 
 
Closeness 
centrality 
 
Betweenness 
centrality 
Average 
egocentric 
density 
 
Degree 
centrality 
 
Closeness 
centrality 
 
Betweenness 
centrality 
Average 
egocentric 
density 
1 0.136** 0.111* 0.368** -0.055 0.099* 0.065 0.157** 0.036 
2 0.190** 0.158** 0.377** -0.122** 0.212** 0.164** 0.212** -0.007 
3 0.290** 0.240** 0.315** -0.120** 0.388** 0.278** 0.053 0.024 
4 0.320** 0.282** 0.322** -0.060 0.438** 0.335** 0.086* 0.024 
5 0.420** 0.369** 0.355** -0.039 0.470** 0.348** 0.132** 0.029 
6 0.480** 0.436** 0.395** -0.061 0.415** 0.352** 0.179** 0.004 
7 0.363** 0.371** 0.390** -0.082** 0.339** 0.307** 0.195** -0.006 
8 0.440** 0.383** 0.432** -0.104** 0.350** 0.304** 0.344** -0.060* 
9 0.526** 0.395** 0.564** -0.111** 0.445** 0.279** 0.390** -0.067** 
10 0.571** 0.394** 0.614** -0.119** 0.520** 0.306** 0.475** -0.087** 
11 0.576** 0.383** 0.661** -0.117** 0.550** 0.293** 0.496** -0.079** 
12 0.453** 0.337** 0.551** -0.119** 0.452** 0.256** 0.431** -0.079** 
13 0.405** 0.333** 0.576** -0.104** 0.376** 0.224** 0.380** -0.060** 
14 0.359** 0.294** 0.507** -0.117** 0.326** 0.171** 0.267** -0.062** 
15 0.316** 0.278** 0.453** -0.106** 0.266** 0.154** 0.202** -0.057** 
16 0.244** 0.264** 0.345** -0.121** 0.219** 0.198** 0.221** -0.072** 
Lowest 
correlation1  0.136 0.111 0.315 -0.122 0.099 0.154 0.132 -0.087 
Highest 
correlation1 0.576 0.436 0.661 -0.104 0.550 0.352 0.496 -0.060 
Average of  
correlation 
coefficients1 0.380 0.314 0.452 -0.112 0.367 0.265 0.278 -0.069 
** Correlation is significant at the 0.01 level 
* Correlation is significant at the 0.05 level 
1 Only coefficients significant at the 0.01 or 0.05 level were considered 
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Table 6: The results for all the hypotheses calculated in the complete network 
H# Correlation                 H confirmed?  H# Correlation                       H confirmed? 
H1a strongly correlated YES H1b strongly correlated YES 
H2a moderately correlated YES H2b moderately correlated YES 
H3a moderately correlated YES H3b moderately correlated YES 
H4a inverse relationship NO H4b inverse relationship NO 
H5a weakly correlated NO H5b weakly correlated NO 
H6a strongly correlated YES H6b moderately correlated YES 
 
Table 7: The results for all the hypotheses calculated in the subnetworks 
H# Correlation                 H confirmed?  H# Correlation                       H confirmed? 
H1a moderately correlated YES H1b moderately correlated YES 
H2a moderately correlated YES H2b weakly correlated YES 
H3a moderately correlated YES H3b weakly correlated YES 
H4a inverse relationship NO H4b inverse relationship NO 
 
Table 8: Overlapping of stars, QQ-stars and highly cited scientists with gatekeepers 
 Stars 
Very important 
gatekeepers Gatekeepers 
Redundant 
intermediaries 
Internal 
inventors 
External 
inventors Total 
Prolific onlya 11 (38%) 6 (21%) 3 (10%) 9 (31%) 29 (100%) 
Stars onlyb 9 (50%) 6 (33%) 3 (17%) 18 (100%) 
Superstars 4 (100%) 4 (100%) 
All prolificd  24 (47%) 12 (24%) 3 (6%) 12 (24%) 0 (0%) 51 (100%) 
All starsc  13 (59%) 6 (27%) 0 (0%) 3 (14%) 0 (0%) 22 (100%) 
QQ-stars 
Very important 
gatekeepers Gatekeepers 
Redundant 
intermediaries 
Internal 
inventors 
External 
inventors Total 
QQ-prolific onlya 6 (26%) 7 (30%) 2 (9%) 7 (30%) 1 (4%) 23 (100%) 
Stars onlyb 5 (26%) 5 (26%) 9 (48%) 19 (100%) 
QQ-superstars 2 (67%) 1 (33%) 3 (100%) 
All QQ-prolificd  13 (29%) 12 (27%) 2 (4%) 17 (38%) 1 (2%) 45 (100%) 
All QQ-starsc  7 (32%) 5 (23%) 0 (0%) 10 (45%) 0 (0%) 22 (100%) 
Highly cited  
Very important 
gatekeepers Gatekeepers 
Redundant 
intermediaries 
Internal 
inventors 
External 
inventors Total 
All highly cited 6 (22%) 7 (27%) 6 (22%) 6 (22%) 2 (7%) 27 (100%) 
a  Only inventors who are prolific but are not considered to be also stars or superstars 
b  Only stars who are not considered to be also superstars 
c  All prolific inventors (including stars and superstars) 
d  All stars (including superstars) 
